Earlier this year, the team at NorthStar VETS in New Jersey shared the story of Stella in a guest post to the VetDC blog. Stella had been diagnosed with canine lymphoma in March 2017. She nearly completed two cycles of conventional chemotherapy when the cancer once again began to progress.
Looking for another way to address the disease, Jennifer Kim, DVM, DACVIM (Oncology) decided to try a protocol using TANOVEA-CA1 (rabacfosadine for injection), the first FDA conditionally approved drug for the treatment of lymphoma in dogs. One week after Stella received treatment, her cancer was in remission with no reported side effects.
An Optimistic Outlook Following TANOVEA-CA1 Treatment
Given the rapid return of Stella’s cancer following her initial response to conventional chemotherapy treatment, her owners were wondering if they would see the same outcome with TANOVEA-CA1. We are pleased to report that NorthStar VETS recently contacted us to say that Stella continues to be happy, healthy and full of energy following her course of TANOVEA-CA1 treatment.
While there is no guarantee that all dogs will have the same experience as Stella, her case is another example of the potential for positive results through the use of this novel cancer-fighting drug, which:
- Accumulates in rapidly dividing lymphoma cells and kills them
- Produced a 77% overall response rate in clinical testing
- Has demonstrated responses both in dogs new to treatment and those who are not responding to conventional chemotherapy
- Is administered in one dose every three weeks for a total of only five treatment visits
To learn more about TANOVEA-CA1, visit www.vet-dc.com/tanovea or talk with your veterinarian.
Important Safety Information: TANOVEA®-CA1 (rabacfosadine for injection) is not for use in humans and should be kept out of the reach of children. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and can cause birth defects and affect female and male fertility. Pregnant and breast-feeding women should not prepare or administer the product. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA®-CA1. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Most common adverse reactions included diarrhea, neutropenia, hyporexia, weight loss, and lethargy. Please see the package insert for full prescribing information.